Request Sample Inquiry
Dystrophin Market

Dystrophin Market

Dystrophin Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

168

Base Year:

2022

Date

Jan - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1251

Segments Covered
  • By Product By Product Exondys51, Translarna, Emflaza, Others
  • By Approach By Approach Exon Skipping, Anti-Inflammatory Therapy, Stop Codon Read-Through, Others Approaches
  • By Region By Region North America, Latin America, Europe, Asia Pacific, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 1.46 Billion
Revenue 2030Revenue 2030: USD 29.53 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 45.60%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst

Research Methodology: Dystrophin Market by Product by Approach by Region - Global Market Assessment, 2021 - 2028

Secondary Research

Primary Research:

Data Triangulation and Market Size Estimations

FAQ
Frequently Asked Question
  • The global Dystrophin valued at USD 1.46 Billion in 2022 and is expected to reach USD 29.53 Billion in 2030 growing at a CAGR of 45.60%.

  • The prominent players in the market are PTC Therapeutics, Sarepta Therapeutics, BioMarin Pharmaceutical Inc, Wave Life Sciences, Bristol-Myers Squibb and Catabasis, Pharmaceuticals among others..

  • The market is project to grow at a CAGR of 45.60% between 2023 and 2030.

  • The driving factors of the Dystrophin include

    • Emergence of Mutation-Specific Therapies, Rising Incidence of the Condition, and Improved Diagnostics

  • North America was the leading regional segment of the Dystrophin in 2022.